Global Health Ltd

Q1 FY26Healthcare Services

Global Health Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹1,410

Market cap₹37.9K Cr

P/E66.2

Updated23 Aug 2026

Read4 min read

The short version

Medanta expects continued strong growth in patient volumes, evidenced by 14% inpatient and 13% outpatient volume growth year-on-year in Q1 FY26. Medanta projects strong growth opportunities driven by expansion and acquisitions aligned with their ecosystem and financial logic (Page 17).

From Global Health Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Medanta expects continued strong growth in patient volumes, evidenced by 14% inpatient and 13% outpatient volume growth year-on-year in Q1 FY26.
Developing hospitals such as Lucknow and Patna show significant momentum towards operational maturity with increasing occupancy and volumes.
Expansion projects (South Delhi, Mumbai, Pitampura) are progressing, though expected commissioning timelines are uncertain; FY 2029-2030 is a tentative target.
New hospitals and bed capacity expansion (e.g., Noida starting with 300 beds scaling up, Ranchi expansion) will further drive volume growth.
Growth in revenue driven by a mix of higher realizations, more complex procedures (like oncology, robotic surgeries), and improved specialty mix.
International patient revenue, especially from Gurugram, is growing but remains a smaller portion of revenue.

2 more points management made on revenue & sales performance

Profitability & Margins

Medanta projects strong growth opportunities driven by expansion and acquisitions aligned with their ecosystem and financial logic (Page 17).
They plan to invest heavily in latest technology and completion of existing hospital build-outs, expecting bulk expenditure in later construction years (Page 17).
EBITDA and PAT showed substantial YoY growth: 23% and 50% respectively in Q1 FY26, indicating robust profitability momentum (Page 4).
ARPOB growth in mature hospitals expected at 3%-7% annually, supported by increased realization and operational efficiencies (Page 12).
Developing hospitals exhibit potential for ARPOB improvement as PPP business grows and operational efficiencies improve (Page 12).

2 more points management made on profitability & margins

See what Global Health Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Medanta has a strong cash position with plenty of growth opportunities and ongoing capex commitments, particularly for building out existing hospitals in Delhi, Mumbai, and Guwahati. Bulk of this hospital build-out spend occurs in the last year of construction.
The company plans to operationalize the new 550-bed Noida hospital starting with about 300 beds, scaling to full capacity based on demand.
They are open to acquisitions, including traditional M&A, O&M contracts, and asset-light models, provided the acquisition fits Medanta’s quality standards, geographical strategy, and financial logic.

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹919 Cr

Rev 1Mar 1

2Chandan Healthca₹590 Cr

Rev 1Mar 3

3₹66.2K Cr

Rev 2Mar 1

4₹1.8K Cr

Rev 2Mar 2

5₹649 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The transcript does not mention any specific plans for current or future fundraising through debt or equity.
The company highlighted having a strong balance sheet and a comfortable cash position with good cash on hand.
Management emphasized focusing on capital deployment towards acquisitions, greenfield projects, and investment in technology, rather than raising new funds at present.

2 more points management made on fundraising & capital structure

See what Global Health Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention the current or expected order book or pending orders for Medanta. However, key points related to growth opportunities and projects include: - Medanta has a broad expansion pipeline with 2,000 beds planned over the next 3-4 years. - Near-term target to add 1,000 beds supported by advanced technology and expanded clinical teams. - Upcoming launch of 550-bed Medanta Noida facility expected operational soon. - Operationalized a 110-bed hospital in Ranchi recently. - Ongoing interior fit-out and commissioning of Tower B in Patna and floors in Lucknow to increase capacity.

2 more points management made on order book & pipeline

Global Health Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹142 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Global Health's management said in earlier quarters

Others in Healthcare Services this season

Aster DM Quality (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
Dr Agarwal's Hea (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
Syngene International Ltd (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
Yatharth Hospit. (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Global Health Ltd Q1 FY26 results?

What is Global Health Ltd share price analysis?

Global Health Ltd currently shows a neutral. The stock trades at a P/E of 66.2 with a market cap of ₹37,919 Cr. Investors should review the full earnings analysis for detailed insights.

Is Global Health Ltd planning capital expenditure?

Medanta has a strong cash position with plenty of growth opportunities and ongoing capex commitments, particularly for building out existing hospitals in Delhi, Mumbai, and Guwahati.

Keep Global Health Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.